FierceBiotech

Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alend

New 2-Year Open-Label Study Shows More Than 90 Percent of Patients Preferred Prolia Injection Every Six Months Over Weekly Oral Alendronate THOUSAND OAKS, Calif., March 23, 2011 /PRNewswire/ -- Amgen ...
FiercePharma

Study Shows Adjuvant Prolia Therapy Reduced Fractures by 50 Percent in Postmenopausal Women With Non-Metastatic Breast Cancer

THOUSAND OAKS, Calif., June 1, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced results from a randomized, double-blind, placebo-controlled, multicenter Phase 3 study evaluating the treatment ...
Insurancenewsnet.com

New Data Show Consistent Safety Profile For Up To 10 Years With Prolia® (Denosumab) In Postmenopausal Women With Osteoporosis

Prolia is administered as a single subcutaneous injection of 60 mg once every six months. Please see the Important Safety Information below. Important Safety Information (U.S.) Prolia is ...
Insurancenewsnet.com

NEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC FRACTURE RISK COMPARED TO ALENDRONATE

--Amgen today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia ® injection reduced fracture ...
The Financial

Amgen : FDA Accepts SBLA For Prolia

The FINANCIAL — Amgen on October 9 announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Prolia (denosumab) for ...